A Single Arm Trial of Toripalimab With Neoadjuvant Carboplatin and Paclitaxel for Locally Advanced Esophageal Squamous Cell Carcinoma
Latest Information Update: 07 Feb 2024
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.
- 01 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research